CN1037934C - 含赖氨酸氯胺烟酸盐的药用软胶囊 - Google Patents

含赖氨酸氯胺烟酸盐的药用软胶囊 Download PDF

Info

Publication number
CN1037934C
CN1037934C CN93107267A CN93107267A CN1037934C CN 1037934 C CN1037934 C CN 1037934C CN 93107267 A CN93107267 A CN 93107267A CN 93107267 A CN93107267 A CN 93107267A CN 1037934 C CN1037934 C CN 1037934C
Authority
CN
China
Prior art keywords
lysine
clonixin
salt
polyethylene glycol
capsule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN93107267A
Other languages
English (en)
Other versions
CN1083702A (zh
Inventor
C·A·瓦斯凯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
S A A I - C - F
Original Assignee
S A A I - C - F
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by S A A I - C - F filed Critical S A A I - C - F
Publication of CN1083702A publication Critical patent/CN1083702A/zh
Application granted granted Critical
Publication of CN1037934C publication Critical patent/CN1037934C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

长期稳定、易用标准制造设备生产并且能提供口服后就立即产生治疗活性的快速作用且比目前市场上出售的赖氨酸氯胺烟酸盐片剂的有害副作用小的软明胶胶囊。其含作为活性成分的赖氨酸氯胺烟酸盐的填充物基于含平均分子量为约200-1000的聚乙二醇的亲水性基质、甘油(占3-10重量%)和水(5-15%)。它们对疼痛和炎症有效。

Description

含赖氨酸氯胺烟酸盐的药用软胶囊
本发明涉及含以镇痛和消炎剂赖氨酸氯胺烟酸盐为活性成分的口服药用组合物。
2-[(3-氯-2-甲基苯基)氨基]-3-吡啶羧酸的2-赖氨酸盐即赖氨酸氯胺烟酸盐已在专利说明书DE 2253134和US 3973027中作了描述。在这两篇说明书中提供了口服制剂、肠道外使用制剂以及直肠使用制剂的参考。
口服是使用赖氨酸氯胺烟酸盐的优选途径，但片剂是本领域公知并存在于市场上的唯一制剂类型。然而，人们已经注意到服用赖氨酸氯胺烟酸盐的固体片剂或装粉的硬胶囊会产生包括消化道的某些局部侵蚀问题。另一方面，口服该药后产生治疗作用的时间是个要着重考虑的问题：从病人的角度出发，非常期望药物能尽快解除疼痛或炎症。因此，开发能提供更快速的治疗作用并降低不适的赖氨酸氯胺烟酸盐的口服药用制剂是有意义的。
软弹性明胶胶囊广泛用来代替药品、维生素、饮食补品等的口服粉装硬胶囊或片剂。病人常更喜欢服用这些软胶囊，因为它们比常规硬胶囊或片剂易于吞咽。
由于赖氨酸氯胺烟酸盐是具较强水溶性的化合物，因此软明胶胶囊制剂面临壳的脆裂并伴随相应的填充物料漏出问题。如果这样，防止赖氨酸氯胺烟酸盐在以溶液或分散体形式填充时的氧化是个附带的问题。
本发明的目的是提供含有效单位剂量赖氨酸氯胺烟酸盐的软明胶胶囊，所述胶囊为长期稳定、易用标准制造设备生产、以及能提供口服胶囊后就立即产生治疗活性的快速作用，且比目前市场上出售的赖氨酸氯胺烟酸盐片剂的有害付作用小。
本发明的具体例子是软明胶胶囊型的药物剂量单位形式，其特征在于：其填充物包括作为活性成分的赖氨酸氯胺烟酸盐、平均分子量为约200-1000的聚乙二醇、以及按填充物总重量计3-10％的甘油和5-15％水。每剂量单位含赖氨酸氯胺烟酸盐20-300mg为宜、125mg为佳。优选平均分子量为约400的聚乙二醇。如果需要，胶囊填充物可含附加成分例如防腐剂、矫味剂和/或增甜剂。赖氨酸氯胺烟酸盐实际上是溶在填充物中而且当胶囊外壳溶解时它能迅速释放到消化道中。
本发明的填充物可以使用常规软明胶胶囊外壳。一个常规外壳的配方包括约30-35重量份明胶、约15-48重量份增塑剂如甘油或山梨醇以及约16-40重量份水。此外明胶外壳可以含防腐剂例如小部分混合的对羟苯甲酸酯类。在常规方法中是将明胶组合物混合并在真空条件下熔化。胶囊可用常规方法和设备同时被制成和填充。通常借助于水将明胶胶囊制成所需的形状和大小以使它们易于吞咽。制得的胶囊溶于水和胃肠液。
用在本发明的填充物中的聚乙二醇的平均分子量的范围(约200-1000)是很关键的，因为较低分子量的聚乙二醇往往引起通过常规软明胶胶囊外过的扩散。用较高分子量的聚乙二醇又往往会导致太粘不能用泵抽的媒液而难于用常规设备生产。
在相当于本发明的剂量单位的填充物中甘油的含量(3-10％)和水的含量(5-15％)对于降低任何不良的聚乙二醇和软胶囊外壳间的相互作用很关键。甘油和水通过在填充物和软明胶外壳的含水量间建立一种平衡而起润湿剂作用。甘油同样起平衡增塑剂的作用以使聚乙二醇不从软明胶胶囊外壳中去除过量的增塑剂。因此，水和甘油能防止聚乙二醇使软明胶胶囊变硬、变脆以及在贮运期间易受损和泄漏。按照本发明的优选的填充物组合物是实施例1中的那些组合物。
事实上赖氨酸氯胺烟酸盐被置于胶囊填充物的溶液中，因此当外壳溶解时，它可以迅速释放到消化道中，由此得到比本领域公知的相应片剂的生物利用度高的本发明胶囊。这一特征由实施例2的药物动力学结果作了说明，该特征表示对病人能产生更迅速的治疗作用，因此优于市场上目前的片剂。
服用本发明的剂量单位形式具有另一个优点：当外壳溶解时，赖氨酸氯胺烟酸盐可非常迅速地扩散至其环境中，因此局部侵蚀及其相关的损害和不适较目前的片剂小。
本发明胶囊易于用标准的制造设备生产并证明在高湿度条件下可以稳定达一年以上，见附在实施例3中的说明。
            实施例1
赖氨酸氯胺烟酸盐软明胶胶囊的制备
制备具表1中所示的每个胶囊的组合物的两种填充物料。将该填充物料在氮气气氛中充分混合并将它们装入常规软明胶外壳中。该填充物料证明是非胀流型体并适于常规软明胶胶囊生产工艺，例如在US2288327和US 2318718中所公开的。此外，形成胶体的填充物料具温度稳定性并且不会从软的弹性明胶外壳中消除过量的水或增塑剂。
              表1典型的胶囊填充组合物(按mg/胶囊)成份：                填充物A   填充物B赖氨酸氯胺烟酸盐：    125       125聚乙二醇400           344       293无水甘油               35        31水                     56        50
              实施例2
赖氨酸氯胺烟酸盐的软明胶胶囊和片剂间的药物动力学比较试验
常规药物动力学比较研究用28个健康禁食的自愿者来完成。其中14人接受单一的125mg剂量市场上买到的赖氨酸氯胺烟酸盐片剂，而另外14人接受同样剂量的表1中填充物组合物A的软明胶胶囊。得到的药物动力学结果见表2。
                表2两种药用形式的药物动力学参数参数          明胶胶囊   片剂、t_(h)        0.17       0.29tmax(h)       0.5        1.0AUC(μg/h/ml)  10.36      10.09Cmax(μg/ml)  4.8        5.6注：t_＝半衰期；tmax＝达到Cmax的时间
AUC＝曲线下面积；Cmax＝最大浓度。
               实施例3
赖氨酸氯胺烟酸盐软明胶胶囊的稳定性试验
用36个月的时间在温度为20-25℃及相对湿度为50-70％的条件下，对按实施例1制得的两种典型的软明胶胶囊的稳定性进行了研究，结果表明：胶囊稳定，无脆裂迹象并且活性成分得因例如氧化而发生改变。

Claims (4)

1.软明胶胶囊类型的药用剂量单位形式，其特征在于：其填充物包括作为活性成分的赖氨酸氯胺烟酸盐、平均分子量为200-1000的聚乙二醇、以及按填充物总重量计3-10％的甘油和5-15％的水。
2.按照权利要求1的剂量单位，其中赖氨酸氯胺烟酸盐的含量为20-300mg。
3.按照权利要求2的剂量单位，其中赖氨酸氯胺烟酸盐的含量为125mg。
4.按照前述任一权利要求的剂量单位，其中聚乙二醇的平均分子量为400。
CN93107267A 1992-06-16 1993-06-16 含赖氨酸氯胺烟酸盐的药用软胶囊 Expired - Fee Related CN1037934C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4219702A DE4219702A1 (de) 1992-06-16 1992-06-16 Pharmazeutische Weichkapseln enthaltend Lysinclonixinat und ein Verfahren zu dessen Herstellung
DEP4219702.3 1992-06-16

Publications (2)

Publication Number Publication Date
CN1083702A CN1083702A (zh) 1994-03-16
CN1037934C true CN1037934C (zh) 1998-04-08

Family

ID=6461132

Family Applications (1)

Application Number Title Priority Date Filing Date
CN93107267A Expired - Fee Related CN1037934C (zh) 1992-06-16 1993-06-16 含赖氨酸氯胺烟酸盐的药用软胶囊

Country Status (13)

Country Link
EP (1) EP0574822A1 (zh)
JP (1) JPH0665078A (zh)
KR (1) KR940000108A (zh)
CN (1) CN1037934C (zh)
AU (1) AU656078B2 (zh)
CA (1) CA2098410A1 (zh)
DE (1) DE4219702A1 (zh)
FI (1) FI932768A (zh)
IE (1) IE930446A1 (zh)
IL (1) IL105870A (zh)
MX (1) MX9303582A (zh)
NO (1) NO932097L (zh)
ZA (1) ZA934222B (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19849848A1 (de) * 1998-10-29 2000-05-04 Lohmann Therapie Syst Lts Oral applizierbare, mit Flüssigkeit spontan zerfallende therapeutische Darreichungsform und Verfahren zu ihrer Herstellung
KR20030042935A (ko) * 2001-11-26 2003-06-02 알앤피코리아 주식회사 클로닉신리신 제제

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4144332A (en) * 1976-01-05 1979-03-13 The Regents Of The University Of Michigan Process for alleviating proliferative skin diseases
EP0492747A2 (en) * 1990-11-26 1992-07-01 Roemmers S.A.I.C.F. Pharmaceutical preparation for topical application

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3337570A (en) * 1965-10-23 1967-08-22 Schering Corp Substituted nicotinic acids and method for the manufacture thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4144332A (en) * 1976-01-05 1979-03-13 The Regents Of The University Of Michigan Process for alleviating proliferative skin diseases
EP0492747A2 (en) * 1990-11-26 1992-07-01 Roemmers S.A.I.C.F. Pharmaceutical preparation for topical application

Also Published As

Publication number Publication date
MX9303582A (es) 1994-04-29
CN1083702A (zh) 1994-03-16
FI932768A0 (fi) 1993-06-16
IL105870A0 (en) 1993-10-20
CA2098410A1 (en) 1993-12-17
JPH0665078A (ja) 1994-03-08
NO932097L (no) 1993-12-17
NO932097D0 (no) 1993-06-09
FI932768A (fi) 1993-12-17
AU656078B2 (en) 1995-01-19
IL105870A (en) 1996-12-05
IE930446A1 (en) 1993-12-29
AU4000993A (en) 1993-12-23
ZA934222B (en) 1994-01-17
DE4219702A1 (de) 1993-12-23
EP0574822A1 (de) 1993-12-22
KR940000108A (ko) 1994-01-03

Similar Documents

Publication Publication Date Title
US4800083A (en) Sustained release method and product
RU2121344C1 (ru) Лекарственная форма двухфазного действия с высвобождением для липофильных лекарственных препаратов и способ ее получения
CA2362932C (en) Pharmaceutical composition containing proton pump inhibitors
CA1213218A (en) Long-acting formulation of cefaclor
EP0152292A2 (en) Acetaminophen gelatin capsules
JPS6322032A (ja) ゼラチン封入徐放性組成物及びその製造方法
EP1275381A4 (en) SOLID COATED PREPARATIONS WITH TEMPERATURE RELEASE FOR ORAL ADMINISTRATION
EP0819004A1 (en) Pharmaceutical composition containing proton pump inhibitors
EP0719548A1 (en) Gelling agent for polyethylene glycol
JPS61183220A (ja) 鎮痛性を有する医薬組成物
CN1037934C (zh) 含赖氨酸氯胺烟酸盐的药用软胶囊
US5626872A (en) Pharmaceutical soft capsules containing lysine clonixinate and a process for their preparation
EP0422290A1 (en) Novel drug delivery system
US20040146537A1 (en) Oily wax matrix suspension formulation comprising pharmacologically active agents
EP0152432B1 (en) Sustained release method and product
RU2108787C1 (ru) Фармацевтические мягкие капсулы, содержащие лизинхлониксинат, способ их получения
US20050175686A1 (en) Drug delivery system using a solubilized gelatin shell composition and unit dose drug delivery using a special shape soft gelatin capsule
JPS5865213A (ja) ｄｌ−２−（４，８，１２−トリメチルトリデシル）−２，５，７，８−テトラメチル−６−クロマニルニコチネ−ト軟カプセル剤
WO2005032516A1 (en) Formulation and manufacturing process of self-microemulsified aceclofenac soft capsules
MXPA01008525A (en) Pharmaceutical composition containing proton pump inhibitors
CA2000482A1 (en) Drug delivery system
IE893287A1 (en) Novel drug delivery system
EP0627220A1 (en) Pharmaceutical compositions for the treatment of thalassemia

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee